title: Irbesartan increased PPARγ activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction.
abstract: The effect of the PPARγ agonistic action of an AT(1) receptor blocker, irbesartan, on adipose tissue dysfunction was explored using atherosclerotic model mice. Adult male apolipoprotein E-deficient (ApoEKO) mice at 9 weeks of age were treated with a high-cholesterol diet (HCD) with or without irbesartan at a dose of 50mg/kg/day for 4 weeks. The weight of epididymal and retroperitoneal adipose tissue was decreased by irbesartan without changing food intake or body weight. Treatment with irbesartan increased the expression of PPARγ in white adipose tissue and the DNA-binding activity of PPARγ in nuclear extract prepared from adipose tissue. The expression of adiponectin, leptin and insulin receptor was also increased by irbesartan. These results suggest that irbesartan induced activation of PPARγ and improved adipose tissue dysfunction including insulin resistance.
authors.affiliation: Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa, Tohon, Ehime 791-0295, Japan.
authors.forename: Masaru
authors.initials: M
authors.lastname: Iwai
authors.forename: Harumi
authors.initials: H
authors.lastname: Kanno
authors.forename: Izumi
authors.initials: I
authors.lastname: Senba
authors.forename: Hirotomo
authors.initials: H
authors.lastname: Nakaoka
authors.forename: Tomozo
authors.initials: T
authors.lastname: Moritani
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Horiuchi
mesh_terms: D052438:Adipocytes, White / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D052436:Adipose Tissue, White / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics; D050197:Atherosclerosis / Q000378:metabolism* / Q000473:pathology; D015415:Biomarkers / Q000378:metabolism; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D002452:Cell Count; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D004247:DNA / Q000378:metabolism; D007328:Insulin / Q000378:metabolism / Q000494:pharmacology; D000077405:Irbesartan; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D011485:Protein Binding; D013777:Tetrazoles / Q000008:administration & dosage*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001057:Apolipoproteins E; D015415:Biomarkers; D001713:Biphenyl Compounds; D002791:Cholesterol, Dietary; D007328:Insulin; D047495:PPAR gamma; D013777:Tetrazoles; D004247:DNA; D000077405:Irbesartan